˿����ƵAPP

This article from  discusses how life insurers can navigat...

It is never easy or enjoyable to deliver bad news to a customer. In an article that , explore new strategies in...

In this Inside ˿����ƵAPP interview, Natalie Ho discusses ˿����ƵAPP’s refreshed brand, including the inspiration behind its key visual elements.

In an aging world, understanding and responding to a growing retirement protection gap is not just an economic and societal imperative; it's a significant opportunity for life insurers. ˿����ƵAPP’s David Lipovics offers lessons learned from the success of pension risk tran...

This article delves into the theme of World Food Day 2023, exploring how water can impact human health, as well as the effects of climate change and environment factors on the accessibility of clean and safe water.

As discoveries within the field of genetics grow exponentially, the field's importance to insurance medicine continues to grow. In this Inside ˿����ƵAPP interview, ˿����ƵAPP Consultant Geneticist Dr. Sajel L. Kana, MD, FAAP, FACMG, describes her commitment to genetics a...

Responding to customer demands for action on climate change, insurers are exploring “green insurance” products and approaches that raise awareness around sustainability and directly support green initiatives.

This article from provides an overview of mortality modeling under the survival analysis framework, machine learning methods, ext...

This is the second article of a four-part series that will also include an overview and articles exploring the survey’s impl...

In this article from On the Risk, Dr. Lauren Garfield explores the increased use of GLP-1 receptor agonist drugs to combat obesity and the potential impact on underwriting.

This article, the second of two parts, provides a comprehensive review of the insurance medicine view of ASD and issues around its assessment when underwriting. Read more about autism through a clinical lens in 

This article provides background on bladder cancer, with a particular focus on current and in-development treatments for non-muscle-invasive disease.